CLL

expert perspectives

by Tom Iarocci, MD

Expert Perspectives delivers health care providers with insights from key thought leaders on the latest advancements and current practices in medic......READ MORE

expert roundtables

by Jennifer R. Brown, MD, PhD; Anthony Mato, MD, MSCE; and Susan O’Brien, MD

The most appropriate way to combine and/or sequence the novel agents remains to be determined; however, an abundance of data support the use of ibr......READ MORE

expert roundtables

by Jennifer R. Brown, MD, PhD; Anthony Mato, MD, MSCE; and Susan O’Brien, MD

17p deletion (del[17p]) and/or aberrant TP53 have historically been considered high-risk categories in patients with chronic lymphocytic leukemia (......READ MORE

patient care perspectives

by Susan O’Brien, MD

Treatments for chronic lymphocytic leukemia (CLL) vary in efficacy, safety, routes of administration, and cost. With an increasing number of availa......READ MORE

patient care perspectives

by Anthony Mato, MD, MSCE

Based on the available data, patients with chronic lymphocytic leukemia (CLL) being treated with novel agents such as ibrutinib or venetoclax can b......READ MORE